C4 Therapeutics raises $73 mln
C4 Therapeutics said Thursday it closed a $73 million Series A round of financing led by Cobro Ventures. Also participating were Cormorant Asset Management, The Kraft Group, EG Capital Group and angel investors. Other investors include Roche and Novartis. Cambridge, Massachusetts-based C4 is developing novel treatments in the field of targeted protein degradation using proprietary Degronimid™ technology.
7 January 2016•4 mins read
